On February 9, 2021, Nanjing Yaojie Ankang Biotechnology Co., Ltd. (referred to as "Yaojie Ankang") announced the closing of its C+ round of financing of US$50 million+. This round of financing was led by Cornerstone Capital and followed by China Merchants Capital. The original shareholders SDIC Venture and Nanjing Fengling Capital continued to increase their holdings. China Renaissance acted as the exclusive financial advisor to the transaction.

 

　　Yaojie Ankang is a clinical stage platform-type small molecule innovative drug research and development company with strong research and development capabilities. Taking global innovation as the standard and aiming to truly solve unmet clinical needs, based on the team's solid innovation capabilities and first-class international concepts, it has built a wealth of innovation pipelines around tumors and immunity, including the first-in -Class products and highly differentiated Best-in-Class products. Yaojie Ankang has original capabilities and resources for small molecule drug discovery and development, and has established a complete and efficient R&D system and platform with various core capabilities.

　　Relying on the team's strong R&D capabilities and efficient execution, Yaojie Ankang has obtained 4 innovative products and multiple preclinical products that are completely independently developed and have entered global clinical development in the four years since the company was founded. The most advanced TT-00420 is an innovative product with First-in-Class potential, a kinase inhibitor with a unique mechanism, and is currently undergoing Phase 1 clinical trials in China and the United States. The product has been granted orphan drug designation by the U.S. FDA for cholangiocarcinoma indications, and a Phase 2 registrational clinical trial will be initiated in the U.S. in 2021. There are other highly competitive innovative products in the pipeline, such as a new mechanism of heart failure treatment drug targeting PDE9, which has been in clinical phase 1 in the United States, leading the global segment in this field. In recent years, Yaojie Ankang has taken solid steps in its international strategic layout and has reached cooperation agreements with a number of internationally renowned companies. The most notable cases include the authorization of LGChem's overseas rights and interests with US$350 million to jointly develop highly differentiated treatments. Small molecule inhibitor of VAP-1 for nonalcoholic steatohepatitis (NASH), and strategic R&D cooperation with Teijin Pharma, a well-known Japanese pharmaceutical company, in multiple therapeutic areas. In addition, Yaojie Ankang expects that in 2021, several potential products will be successively advanced to the clinical stage.

　　Mr. Zhang Wei, Chairman of Cornerstone Capital, said: "Yaojie Ankang has completed a 0-1 leap in the field of small molecule innovative drugs, built a complete R&D technology platform and system, and formed a rich and promising product pipeline. The strategic cooperation between LG Chem and Teijin Pharmaceuticals fully verifies the company's innovation strength and global cooperation ability, and represents the recognition of Yaojieankang in the international market. We are highly optimistic about Yaojieankang's excellent R&D system and excellent management team, and will continue to support The company will bring more and more innovative products to the market and bring good news to patients around the world.”

　　Mr. Feng Hongtao, deputy general manager of China Merchants Capital, said: "We attach great importance to the outstanding capabilities of Jie Ankang in four aspects: platform research and development capabilities, which will continue to create innovative and differentiated pipeline products for the company; strong execution capabilities to promote the company's continuous development. Achieve new milestones; pipeline innovation capability, global innovation is the consistent adherence of Yaojie Ankang, starting from clinical needs, with solid research and development capabilities, to bring real good drugs and new drugs to the market with clinical breakthrough significance; international competitiveness, based on China, looking to the world, using first-class standards to create potential product candidates with global competitiveness. China Merchants Capital is very pleased to join hands with Yaojie Ankang, and hopes that through our resources and layout, the company will further develop its outstanding capabilities in the future. , to bring innovative products to patients as soon as possible."

　　Dr. Wu Yongqian, Chairman and CEO of Yaojie Ankang, said: "We are very honored to have the trust and support of new and old shareholders. We will uphold the concept of global innovation and adhere to the value creation strategy of independent innovation and open cooperation. This round of The financing will help us achieve our near-term business goals of commercialization, internationalization and capitalization."

　　Mr. Xie Yijing, Managing Director of Huaxing Capital and Head of the Medical and Life Technology Group, said: "We are honored to continue to accompany Yaojie Ankang to complete a new round of financing. Since the B round, we have been witnessing the company's breakthroughs and achievements New milestones, creating new business models, and opening up more future potential. I believe that with the continuous support of new and old shareholders, Yaojie Ankang will bring more surprises and breakthroughs.”